体外研究
(In Vitro) | Anticancer agent 43 (compound 3a) shows selectivity toward human tumor cells (SI50=28.94)[1].
Anticancer agent 43 (45 μM, 24 h) induces apoptosis via caspase 3, PARP1 and Bax dependent pathways in HepG2 cells[1].
Anticancer agent 43 (45 μM, 24 h) shows no effect on the transition of G1/S phases in HepG2 cells[1].
Anticancer agent 43 (0.7, 45, 55 μM) induces DNA damage in HCT116 cells (Tail DNA=16.1%, OTM=3.7), MCF-7 cells, HepG2 cells (Tail DNA=26.2%, OTM=13.2), Balb/c 3T3 cells (Tail DNA = 8.4%, OTM = 3.5)[1].
Cell Cytotoxicity Assay[1] | Cell Line: | HepG2, MCF-7, HCT116, HeLa, A549, WM793, THP-1, HaCaT, Balb/c3T3 cells | | Concentration: | 0, 1, 10, 100 μM | | Incubation Time: | 72 h | | Result: | Showed cytotoxic action with GI50s of 12.1, 0.7, 0.8, 49.3, 9.7 μM for for HepG2, MCF-7, HCT116, HeLa, A549 cells, low toxicity towards WM793, THP-1, HaCaT, Balb/c 3T3 cells with GI50s of 80.4, 62.4,98.3,40.8 μM , respectively. |
Apoptosis Analysis[1] | Cell Line: | HepG2 cells | | Concentration: | 45 μM | | Incubation Time: | 24 h | | Result: | Induced apoptosis in HepG2 cells via caspase 3, PARP1 and Bax dependent pathways. |
Western Blot Analysis[1] | Cell Line: | HCT116, MCF-7 cells | | Concentration: | 0.7 μM | | Incubation Time: | 24 h | | Result: | Decreased the expression of Cdk2 protein in HCT116 and MCF-7 cells. |
Cell Cycle Analysis[1] | Cell Line: | HepG2 cells | | Concentration: | 45 μM | | Incubation Time: | 24 h | | Result: | Showed no effect on the transition of G1/S phases in HepG2 cells. |
|
